Dr. Thomas Scullion discusses how to leverage NHP exploratory toxicology studies to guide and explore lead optimization, dosing paradigms, and future GLP studies.
The clinical toxicity of immunotherapy can be unpredictable, often deviating from preclinical research in rodent models. On the other hand, in-vivo research using NHP models to assess immunotoxicity is far more translational, much of the risk out of clinical trials.
In this webinar sponsored by CrownBio, Dr. Thomas Scullion will discuss how to leverage NHP exploratory toxicology studies to inform lead optomization, dosing paradigms and GLP studies. Dr. Scullion will also highlight the translational relevance of NHP models for immunotoxicity research.
Key Topics Include:
- How to design and implement flexible non-GLP NHP exploratory toxicology studies to answer multiple developmental questions, including dosing regimen and immunogenicity endpoints
- How to incorporate in vitro assays using NHP and clinical samples to evaluate immune marker expression prior to starting a study
- How NHPs provide a more translational preclinical model for elucidating immune-related toxicity
- How to leverage exploratory NHP toxicology studies to assess immunotherapy safety, and de-risk future clinical trials
- Learning how you can exploit the advantages of early immuno-safety screens in NHPs in order to de-risk clinical trials
- Identifying and mitigating cytokine release syndrome in early-stage preclinical development
- Developing immunotherapies and optimizing preclinical immuno-safety data
Senior Director of Business Development
Dr. Thomas Scullion has extensive experience guiding clients’ early drug discovery work through to clinical trials. At CrownBio, he specializes in pharmacology, toxicology, and bioanalytics using translational animal models. Thomas holds a PhD in Neuropharmacology, and previously worked at Symbiosis Pharmaceutical Services Limited and Charles River Laboratories.
Crown Bioscience brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease. Our premier Translational Platforms help our clients accelerate their new drug development programs.
Additional Content From Crown Bioscience
What’s Next in Preclinical Cancer Immunotherapy Research?
This webinar will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions.
Analyzing the Suppressive TME in in Vitro Based Assays
Experts describe suppressive tumor immune microenvironment compartments and patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies.
Targeting T Cells Within the Cancer Immunity Cycle
In this webinar, speakers will discuss the role of T cell biology in cancer immunotherapy.
Save Time and Money When Prioritizing Drug Candidates: Using Cell-Based Reporter Assays for Nuclear Receptor Profiling
Dr. Jack Vanden Heuvel discusses the use of cell-based reporter assays for nuclear receptor profiling to efficiently prioritize drug candidates and minimize off-target effects.
Evaluation of TruVivo, an All-Human Hepatocyte Model for Mechanistic DMPK Investigations
Join Diane Ramsden, PhD, and Lindsey Whaley, MS, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences.
Targeting Proteomics to Decipher Biology for the Drug Development Pipeline
Dr. Jeffrey Silva explores the role of mass spectrometry-based proteomics on drug discovery, disease mechanisms, and biomarker identification.